interventional
N/A
1 country
10
To demonstrate the superiority of nicotinamide (NAM) to achieve the complete renal recovery in patients with a persistent acute kidney injury (stage 2 or 3 in KDIGO classification) despite 24h with standard care, between two therapeutic strategies:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 5, 2025
Actual (reported)rate of complete renal recovery (success) assessed at day + 21 post-randomization. The complete renal recovery, (success) will be defined from the estimated glomerular filtration rate (eGFR): - if baseline eGFR is unknown; an eGFR >60ml/min (at day+21 according to the mention above) - if baseline eGFR is available; by the return to baseline eGFR +/- 3.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
NICOTINAMIDE
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
FILM-COATED TABLET
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
NICOTINAMIDE
Named ingredient: Nicotinamide
View registry recordRegistry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Besancon University Hospital Center
Besancon Cedex, 25030, France
Centre Hospitalier Regional De Marseille
Marseille, 13015, France
Centre Hospitalier Universitaire De Toulouse
Toulouse Cedex 9, 31059, France
nephrologist
First Submitted
February 5, 2025
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury
Contact the study team to confirm eligibility.
Centre Hospitalier Universitaire De Nimes
Nimes, 30900, France
Les Hopitaux Universitaires De Strasbourg
Strasbourg Cedex, 67091, France
Centre Hospitalier Universitaire Reims
Reims Cedex, 51092, France
Centre Hospitalier Universitaire De Nantes
Nantes, 44000, France
Hopital Tenon
Paris Cedex 20, 75970, France
Centre Hospitalier Universitaire De Montpellier
Montpellier, 34090, France
Hopital Ambroise Pare
Boulogne-Billancourt, 92100, France